Bayer AG BAYN
Bayer at €88/11x trades in no-man's land between Monsanto deal-sceptics and deal-believers; whether the merger closes or breaks, Bayer shareholders get cake.
Thesis
Greenlight argues Bayer is deeply undervalued at €88/11x earnings because the market is paralyzed by the pending Monsanto acquisition: deal-sceptics sold on announcement while deal-believers refuse to buy until closing certainty arrives, leaving the stock trapped. On a sum-of-parts basis, Bayer's four franchises — pharma (peers 14x), crop protection (20x), consumer health (22x) and animal health (21x, Zoetis comp) — warrant a blended 14-22x multiple, not 11x. If the $128/share Monsanto deal breaks, Bayer re-rates to its pre-deal 14x standalone multiple. If it closes, $1.5B of identified synergies bring the 28x headline price down to an effective ~12x, and the combined company compounds net income at 11.9% CAGR through 2021. Either outcome is a 'cake' scenario.
SCQA
Bayer is a €73bn German life-sciences conglomerate spanning pharmaceuticals, crop science, consumer health and animal health, currently shedding its Covestro chemicals business to focus on four premium life-sciences franchises.
After announcing a $128/share all-cash bid for Monsanto in May 2016, Bayer's stock collapsed to €85/11x earnings as deal-sceptics sold out and deal-believers refused to buy ahead of regulatory closing risk.
Greenlight buys Bayer now, indifferent to outcome: if the Monsanto deal breaks, the stock re-rates to its pre-deal 14x standalone multiple; if it closes, synergies make the headline 28x price an effective 12x.
Sum-of-parts using peer multiples (consumer 22x, animal 21x, crop 20x, pharma 14x) points to meaningful upside from today's 11x; combined pro-forma net income grows at 11.9% CAGR through 2021.
The three reasons
- 1
Bayer trades at 11x earnings vs. blended peer multiples of 14-22x across its four segments
- 2
If Monsanto deal breaks, Bayer re-rates to its pre-deal standalone 14x multiple
- 3
If deal closes, $1.5B synergies cut effective acquisition multiple from 28x to ~12x
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (6)
Notes
Robin Hood Investors Conference presentation by David Einhorn. Long thesis (not activist), but a textbook contrarian SCQA: market is paralyzed by binary Monsanto deal outcome, Greenlight takes the other side with 'wedding cake vs break-up cake' framing. Signature Greenlight navy-gradient + New-Yorker-cartoon aesthetic; narrative craft is far stronger than slide design. Sparse slides (one chart or cartoon + headline, with speaker notes carrying the argument). No stake disclosed. Closing ask is implicit buy-the-stock rather than any governance demand. Peer-gap is shown as a multi-row P/E table (slide 31) rather than a bar chart, but functionally serves the same purpose.